Tradestie Institutional Equity Comparison Engine

REGN vs BNTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

REGN Overall Edge

REGN Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while BNTX counters with relative strength in Valuation. Fundamentally, REGN trades at 14.9x Forward P/E with 30.4% operating margin (+36.3% YoY revenue) versus BNTX at 7.0x Forward P/E and -55.5% operating margin (-15.1% YoY). In options structure, REGN sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against BNTX sits in UNCLASSIFIED (76th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner BNTX
REGN 14.9x vs BNTX 7.0x Fwd P/E
Growth & Margin Winner REGN
Op Margin 30.4% vs -55.5% ยท YoY +36.3% vs -15.1%
Momentum & Technical Winner REGN
1Y +27.3% vs -20.6% ยท 52W Pos 83% vs 4%
Options & Structure Winner REGN
CONSOLIDATION (6th %ile IV) vs UNCLASSIFIED (76th %ile IV)
REGN NASDAQ
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$923.34
-2.35% 1D
Market Cap $97.8B
1M Return +14.61%
1Y Return +27.3%
Forward P/E 14.9x
Unified AI Score
42.6 / 100 HOLD
Tech 19.0 Fund 45.0 Flow 68.0 Mom 56.0
BNTX NASDAQ
BioNTech SE American Depositary Share
Biological Products, (No Diagnostic Substances)
$81.38
-2.26% 1D
Market Cap $20.6B
1M Return -10.86%
1Y Return -20.63%
Forward P/E 7.0x
Unified AI Score
43.3 / 100 HOLD
Tech 22.0 Fund 45.0 Flow 50.0 Mom 68.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: REGN +27.3% BNTX -20.63% Spread: +47.93 pp (REGN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
REGN TTM Op. Margin: 30.4% BNTX TTM Op. Margin: -55.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REGN vs BNTX. Trailing 12-month operating profitability (REGN 30.4% vs BNTX -55.5%) and valuation multiples (REGN 14.9x vs BNTX 7.0x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: REGN (6) vs BNTX (4)
Institutional Metric REGN BNTX Criterion Row Winner
Market Capitalization Scale $97.8B $20.6B Larger Scale REGN
Trailing P/E Ratio Valuation 20.9x 7.0x Lower Multiple BNTX
Forward P/E Ratio Valuation 14.9x 7.0x Lower Multiple BNTX
Revenue Growth (YoY) Growth +36.3% -15.1% Higher Growth REGN
Operating Margin (TTM) Profitability 30.4% -55.5% Higher Margin REGN
Net Profit Margin Profitability 28.5% -60.9% Higher Margin REGN
Return on Equity (ROE) Capital Efficiency 14.9% -8.1% Higher ROE REGN
52-Week Range Position Momentum 83% ($592โ€“$992) 4% ($80โ€“$124) Stronger Trend REGN
Beta / 30D Volatility Risk Regime 0.32ฮฒ ยท 55% Vol 0.81ฮฒ ยท 31% Vol Lower Realized Risk BNTX
Unified Institutional Score Composite Signal 42.6 / 100 (HOLD) 43.3 / 100 (HOLD) Higher Composite BNTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full REGN vs BNTX Buy Guide
REGN CONSOLIDATION
55d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live REGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BNTX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 76th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live BNTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither REGN nor BNTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.